The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), A PET radiotracer designed for the delineation of histone deacetylase expression in cancer

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 683-696

  Zeglis, Brian M ^a   Pillarsetty, NagaVaraKishore ^a   Divilov, Vadim ^a   Blasberg, Ronald A ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

18F FAHA; 18F FESAHA; Histone deacetylase; Hydroxamic acid; PET; SAHA

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ENZYME INHIBITOR; FLUORINE 18; HISTONE DEACETYLASE; N1 [4 [2 FLUOROETHYL]PHENYL] N8 HYDROXYOCTANEDIAMIDE; N1 [4 [2 FLUOROETHYL]PHENYL] N8 HYDROXYOCTANEDIAMIDE F 18; TRACER; UNCLASSIFIED DRUG; VORINOSTAT; ANILIDE; DIAGNOSTIC AGENT; DIPHENYL ETHER DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; N1 (4 (2 FLUOROETHYL)PHENYL) N8 HYDROXYOCTANEDIAMIDE; N1-(4-(2-FLUOROETHYL)PHENYL)-N8-HYDROXYOCTANEDIAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG DESIGN; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; DRUG SCREENING; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TISSUE LEVEL; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR TRANSPORT; MALE; MOLECULAR IMAGING; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVE SITE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIOCHEMISTRY; SCINTISCANNING; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANILIDES; ANIMALS; BIOLOGICAL TRANSPORT; CATALYTIC DOMAIN; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG DESIGN; DRUG STABILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MALE; MICE; MODELS, MOLECULAR; PHENYL ETHERS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOACTIVE TRACERS; RADIOCHEMISTRY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959631545     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.008     Document Type: Article

References (58)

1. Bhalla K.N. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005, 23:3971-3993.
2. Egger G., Liang G., Aparicio A., Jones P. Epigenetics in human diseases and prospects for epigenetic therapy. Nature 2004, 429:457-463.
3. Csordas A. On the biological role of histone acetylation. Biochem J 1990, 265:23-38.
4. Hansen J.C., Nyborg J.K., Luger K., Stargell L.A. Histone chaperones, histone acetylation, and the fluidity of the chromogenome. J Cell Physiol 2010, 224:289-299.
5. Turner B.M. Histone acetylation and control of gene expression. J Cell Sci 1991, 99:13-20.
6. Wade P.A., Pruss D., Wolffe A.P. Histone acetylation: chromatin in action. Trends Biochem Sci 1997, 22:128-132.
7. Lehrmann H., Pritchard L.L., Harel-Bellan A. Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation. Adv Cancer Res 2002, 86:41-65.
8. Rice J.C., Allis C.D. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 2001, 13:263-273.
9. Khan S.N., Khan A.U. Role of histone acetylation in cell physiology and diseases: an update. Clin Chim Acta 2010, 411:1401-1411.
10. Chang H.H., Chiang C.P., Hung H.C., Lin C.Y., Deng Y.T., Kuo M.Y.P. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol 2009, 45:610-614.
11. Kawai H., Li H., Avraham S., Jiang S., Avraham H.V. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer 2003, 107:353-358.
12. Lehmann A., Denkert C., Budczies J., Buckendahl C., Darb-Esfahani S., Noske A., et al. High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo. BMC Cancer 2009, 9.
13. Noonan E.J., Place R.F., Pookot D., Basak S., Whitson J.M., Hirata H., et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009, 28:1714-1728.
14. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., et al. Histone deacetylase 3 (HDAC3) and other class IHDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J Biol Chem 2006, 281:13548-13558.
15. Song J., Noh J.H., Lee J.H., Eun J.W., Ahn Y.M., Kim S.Y., et al. Increased expression of historic deacetylase 2 is found in human gastric cancer. Apmis 2005, 113:264-268.
16. Park J.H., Hong Y.S., Choi P.J., Kim N.Y., Lee K.E., Roh M.S. The overexpresion of histone deacetylase 1 and its relationhip with p16 gene hypermethylation in pulmonary squamous cell carcinoma and adenocarcinoma. Korean J Pathol 2009, 43:107-112.
17. Ganesan A., Nolan L., Crabb S.J., Packham G. Epigenetic therapy: histone acetylation, DNA methylation and anti-cancer drug discovery. Curr Cancer Drug Targets 2009, 9:963-981.
18. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nature 2006, 6:38-51.
19. Marks P.A., Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005, 14:1497-1511.
20. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5:981-989.
21. Dokmanovic M., Marks P.A. Prospects: histone deacetylase inhibitors. J Cell Biochem 2005, 96:293-304.
22. Gray S.G., Ekstrom T.J. The human histone deacetylase family. Exp Cell Res 2001, 262:75-83.
23. De Ruijter A.J., van Gennip A.H., Caron H.N., Kemp S., van Kuilenburg A.B. Histone deacetylases: characterzation of the classical HDAC family. Biochem J 2003, 370:737-749.
24. Marks P.A. Discovery and development of SAHA as an anticancer agent. Oncogene 2007, 26.
25. Breslow R., Jursic B., Yan Z.F., Friedman E., Leng L., Ngo L., et al. Potent cytodifferentiating agents related to hexamethylenebisacetamide. Proc Natl Acad Sci U S A 1991, 88:5542-5546.
26. Richon V.M., Webb Y., Merger R., Sheppard T., Jursic B., Ngo L., et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996, 93:5705-5708.
27. Johnstone R.W., Licht J.D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target?. Cancer Cell 2003, 4:13-18.
28. Kelly W.K., Marks P.A. Drug Insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2:150-157.
29. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5:769-784.
30. Carlisi D., Vassallo B., Lauricella M., Emanuele S., D'Anneo A., Di Leonardo E., et al. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects. Int J Oncol 2008, 32:177-184.
31. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26:5541-5552.
32. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., et al. Structure of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 1999, 401:188-193.
33. Salmi-Smail C., Fabre A., Dequiedt F., Restouin A., Castellano R., Garbit S., et al. Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. J Med Chem 2010, 53:3038-3047.
34. Nagaoka Y., Maeda T., Kawai Y., Nakashima D., Oikawa T., Shimoke K., et al. Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives. Eur J Med Chem 2006, 41:697-708.
35. Bouchain G., Delorme D. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation. Curr Med Chem 2003, 10:2359-2372.
36. Uesato S., Kitagawa M., Nagaoka Y., Maeda T., Kuwajima H., Yamori T. Novel histone deacetylase inhibitors: N-hydroxycarboxamides possessing a terminal bicyclic aryl group. Bioorg Med Chem Lett 2002, 12:1347-1349.
37. Accessed August 31, 2010. http://www.clinicaltrials.gov.
38. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27:5459-5468.
39. Balasubramanian S., Verner E., Buggy J.J. Isoform-specific histone deacetylase inhibitors: The next step?. Cancer Lett 2009, 280:211-221.
40. Tan J.H., Cang S.D., Ma Y.H., Petrillo R.L., Liu D.L. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010, 3.
41. Noureen N., Rashid H., Kalsoom S. Identification of type-specific anticancer histone deacetylase inhibitors: road to success. Cancer Chemother Pharmacol 2010, 66:625-633.
42. Mukhopadhyay U., Tong W.P., Gelovani J.G., Alauddin M.M. Radiosynthesis of 6-([18F]fluoroacetamido)-1-hexanoic anilide ([18F]FAHA) for PET imaging of histone decaetylase (HDAC). J Label Compd Radiopharm 2006, 49:997-1006.
43. Reid A.E., Hooker J., Shumay E., Logan J., Shea C., Kim S.W., et al. Evaluation of 6-([18F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nucl Med Biol 2009, 36:247-258.
44. Nishii R., Mukhopadhhyay U., Yeh H., Sohomonyan S., Volgin A., Alauddin M.M., et al. Non-invasive imaging of histone deacetylase activity in human breast carcinoma xenografts in rat using positron emission tomography (PET) with [18F]-FAHA. J Nucl Med 2007, 48S2:34.
45. Nishii R., Mukhopadhhyay U., Yeh H., Sohomonyan S., Volgin A., Alauddin M.M., et al. PET imaging of histone deacetylase activity in rat brain using 6-([18F]fluoroacetamide)-1-hexanoicanilide. J Nucl Med 2007, 48S2:336.
46. Delano W.L. The PyMOL Molecular Graphics System 2002, Delano Scientific, San Carlos (Calif).
47. Zheng Q.H., Fei X., Liu X., Wang J.W., Stone K.L., Martinez T.D., et al. Comparitive studies of potential cancer biomarkers carbon-11 labeled MMP inhibitors (S)-2-(4'-[11C]-methoxybiphenyl-4-sulonylamino-3-methylbutyric acid and N-hydroxy-(R)-2-[[4'-[11C]methoxy)sulfonyl]benzylamino]-3-methlbutanamide. Nucl Med Biol 2004, 31:77-85.
48. Wagner S., Breyholz H., Law M.P., Faust A., Holtke C., Schroer S., et al. Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methoxyphenyl)sulfonyl](benzyl)- and (3-picolyl)-amino]-3-methyl-butanamide as potential tools for the molecular imaging of activated MMPs with PET. J Med Chem 2007, 50:5752-5764.
49. Zheng Q.H., Fei X., Liu X., Wang J.W., Sun H.B., Mock B.H., et al. Synthesis and preliminary biological evaluation of MMP inhibitor radiotracers [11C]methyl-halo-CGS 27023A analogs, new potential PET breast cancer imaging agents. Nucl Med Biol 2002, 29:761-770.
50. Fei X., Qi-Huang Z., Hutchins G.D., Liu X., Stone K.L., Carlson K.A., et al. Synthesis of MMP inhibitor radiotracers [11C]methyl-CGS 27023A and its analogs, new potential PET breast cancer imaging agents. J Label Compd Radiopharm 2002, 45:449-470.
51. Gediya L.K., Chopra P., Purushottamachar P., Maheshwari N., Njar V.C.O. A new simple and high-yield synthesis of suberoylanilide hydroxamic acid and its inhibitory effect alone of in combination with retinoids on proliferation of human prostate cancer cells. J Med Chem 2005, 48:5047-5051.
52. Wang H., Lim Z.Y., Zhou Y., Ng M., Lu T., Lee K., et al. Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: synthesis, SAR, and in vivo antitumor activity. Bioorg Med Chem Lett 2010, 20:3314-3321.
53. Wang L., Zou X., Berger A.D., Twiss C., Peng Y., Yirong L., et al. Increased expression of histone deacetylases and inhibition of prostate cancer growth and invasion by HDAC inhibitor SAHA. Am J Transl Res 2009, 1:62-71.
54. Xu W., Ngo L., Perez G., Dokmanovic M., Marks P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibition. Proc Natl Acad Sci U S A 2006, 103:15540-15545.
55. Krchnak V. Solid-phase synthesis of biologically interesting compounds containing hydroxamic acid moiety. Mini Rev Med Chem 2006, 6:27-36.
56. Levin J.I. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE. Curr Top Med Chem 2004, 4:1289-1310.
57. Miller M.J. Syntheses and therapeutic potential of hydroxamic acid based siderophores and analogs. Chem Rev 1989, 89:1563-1579.
58. Saban N., Bujak M. Hydroxyurea and hydroxamic acid derivatives as antitumor drugs. Cancer Chemother Pharmacol 2009, 64:213-221.